High-flying Eli Lilly pushes more chips forward with $4.5B 'Medicine Foundry' project

As Eli Lilly has surged to become the most valuable company in biopharma—with a market cap now more than twice that of powerhouse rival Johnson & Johnson largely thanks to its diabetes and weight loss franchise—the Indianapolis company has poured much of its revenue into new investment.